These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Role of oxidative stress in pathogenesis of diabetic nephropathy]. Inoguchi T Nihon Jinzo Gakkai Shi; 2011; 53(7):1016-20. PubMed ID: 22073866 [No Abstract] [Full Text] [Related]
3. [Microinflammation in the pathogenesis of diabetic nephropathy]. Shikata K Nihon Jinzo Gakkai Shi; 2007; 49(5):474-80. PubMed ID: 17695807 [No Abstract] [Full Text] [Related]
4. [Role of chemokines/chemokine receptors in pathogenesis of diabetic nephropathy]. Hara A; Wada T Nihon Jinzo Gakkai Shi; 2011; 53(7):1027-33. PubMed ID: 22073868 [No Abstract] [Full Text] [Related]
5. Diabetic nephropathy: causes and managements. Tripathi YB; Yadav D Recent Pat Endocr Metab Immune Drug Discov; 2013 Jan; 7(1):57-64. PubMed ID: 23227864 [TBL] [Abstract][Full Text] [Related]
6. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617 [TBL] [Abstract][Full Text] [Related]
7. [The protective role of PPARgamma in diabetic nephropathy]. Zang HL; Wang CJ; Yang JC Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):435-8. PubMed ID: 21416961 [No Abstract] [Full Text] [Related]
12. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. Casey RG; Joyce M; Roche-Nagle G; Chen G; Bouchier-Hayes D J Surg Res; 2005 Feb; 123(2):176-81. PubMed ID: 15680375 [TBL] [Abstract][Full Text] [Related]
13. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142 [TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome. Pakala R; Kuchulakanti P; Rha SW; Cheneau E; Baffour R; Waksman R Cardiovasc Radiat Med; 2004; 5(2):97-103. PubMed ID: 15464947 [TBL] [Abstract][Full Text] [Related]
15. [Clinical study on nephrology]. Imai E; Hamano T Nihon Jinzo Gakkai Shi; 2010; 52(1):13-27. PubMed ID: 20166535 [No Abstract] [Full Text] [Related]
16. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116 [TBL] [Abstract][Full Text] [Related]
17. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867 [TBL] [Abstract][Full Text] [Related]